Journal
FUTURE ONCOLOGY
Volume 14, Issue 27, Pages 2861-2874Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0711
Keywords
afatinib; osimertinib; NSCLC; sequential; T790M
Categories
Funding
- Boehringer Ingelheim
- Astra Zeneca
- Pfizer
- Novartis
- Takeda
- Merck
Ask authors/readers for more resources
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials& methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment 10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available